



LCT

living insights

DECEMBER 2014 • ISSUE 4

Published on an occasional basis, *Living Insights* is a source of up-to-date information for followers of the leading Australasian biotechnology company Living Cell Technologies (LCT)

In this edition

- ▶ Message from the CEO
- ▶ Annual General Meeting report
- ▶ An update on NTCELL
- ▶ Cash position



Message from the CEO

Welcome to the December issue of Living Insights. As the year comes to a close, Living Cell Technologies is in great shape in terms of both progress with our science and our financial situation. We've met a number of important milestones this year and are looking forward to 2015.

Among the highlights of the past 12 months:

- Resumed NTCELL® clinical trial
- Regained 100% ownership of NTCELL
- Appointed scientific advisors: **Roger Barker** (Cambridge, UK), **Richard Faull** (Auckland, NZ), **Anne Young** (Harvard, US)
- Formed a collaboration agreement with Centre for Brain Research, Auckland
- Completed implants for all patients in Parkinson's disease trial
- Raised \$4m from New Zealand investors and existing shareholders
- Secured OPF financing of DOL joint venture
- Streamlined IP portfolio and patent strategies

I look forward to building on the strong platform we've established this year and to sharing news of our progress over the coming 12 months.

Wishing you all a very Merry Christmas and a Happy New Year.

Ken Taylor
CEO

Annual General Meeting

The LCT Annual General Meeting was held at the Novotel Ellerslie, Auckland on 18 November. The mood in the room amongst the 40 or so shareholders present was very positive.

At the meeting, Mr Roy Austin and Dr Bernard Tuch were re-elected as directors.


- ▶ [Read the text of Chairman Roy Austin's address to the meeting here](#)
- ▶ [View the Chairman's accompanying presentation here](#)

After the official business, CEO Ken Taylor's presentation covered the company's recent milestones. Head of Research and Development, Dr Jackie Lee, explained in depth what NTCELL® is and how it works in the brain.

Professor Richard Faull, one of LCT's scientific advisors and head of the Centre for Brain Research at The University of Auckland, also addressed the meeting. He discussed the work of the Centre and its collaboration with LCT. This will explore potential opportunities to use LCT's expertise in cell therapies to treat other neurodegenerative disorders such as Huntington's, Alzheimer's and motor neurone diseases.

- ▶ [You can see the CEO's presentation here](#)

Next year's AGM will be held in November in Auckland once again. We hope to see many shareholders there.



An update on NTCELL

The final patient in the Phase I/IIa clinical trial of NTCELL for Parkinson's disease was successfully implanted at Auckland City Hospital earlier this month. The Phase I/IIa clinical trial, led by Dr Barry Snow, is an open-label investigation of the safety and clinical effects of NTCELL in patients who no longer respond to current therapy.

DATE	MILESTONE
September 2013	First patient successfully implanted. DSMB approves further patient recruitment.
August 2014	Second patient successfully implanted.
November 2014	Third and fourth patients recruited.
December 2014	All patients have received implants.
June 2015	Anticipated that results of 26 week trial will be presented at the International Congress of Parkinson's Disease and Movement Disorders.

Our plan is for the findings of the trial to be reviewed by our three scientific advisors ahead of Dr Barry Snow presenting the results at the **19th International Congress of Parkinson's Disease and Movement Disorders** in San Diego in June 2015



Cash position

At the end of the calendar year, LCT is in a strong financial position. The private placement in October raised \$3m and the subsequent share purchase plan which closed at the end of November raised an additional \$1.08m.

As the calendar year draws to a close the company has a cash balance of around \$6.5m which is projected to provide funding for its development program into 2016.

LCT DISCLAIMER: This document contains general background information about the Company's activities current at the date of 16/12/2014. It is information given in summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This should be considered, with or without professional advice, when deciding if an investment is appropriate.

Keep up to date

All announcements, presentations and papers are published on our website: www.lctglobal.com

► **We've updated our fact sheet which you can find on our website here.**



LCT is incorporated in Australia with its operations based in New Zealand.

Australia

Phone: +61 2 9239 0277

Email: info@lctglobal.com

New Zealand

Phone: +64 9 276 2690

Email: info@lctglobal.com

Media & investor enquiries

Rachael Joel,

Botica Butler Raudon

Phone: +64 9 303 3862

Email: rachaelj@botica.co.nz

ASX: LCT OTCQX: LVCLY

Keep in touch with developments at:
www.lctglobal.com

Follow us on Twitter
► [Follow us @LCTglobal](https://twitter.com/LCTglobal)

Are you registered to receive our newsletter?
► [Register here](#)